Polynovo
PolyNovo specializes in developing and commercializing advanced medical devices using its proprietary NovoSorb technology. The company focuses on treating burns, surgical wounds, and providing solutions for Negative Pressure Wound Therapy, positioning itself as a leader in innovative healthcare solutions.
Short position
Polynovo (ASX:PNV) has 7.06% of its shares on issue reported as short positions as of 5 Oct 2026, or about 48,746,700 shares. Over the past 30 days that figure has fallen 0.90 percentage points, and over 90 days it has fallen 1.54 percentage points. Its highest recorded short interest was 14.61% in May 2026. PNV is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PNV community
Research Threads
Bull, bear, catalyst, and news-reaction posts tied directly to PNV.
Start the first PNV research thread
Anchor the conversation with a thesis, a catalyst, or a question worth debating.